SER · Serina Therapeutics, Inc.

Serina Therapeutics’ Q1 2026 results reflect a deliberate ramp-up in clinical execution and financial positioning: net loss widened to $6.9 million from $4.8 million year-over-year, primarily driven by increased R&D ($3.2M vs $3.0M) and G&A ($3.1M vs $2.9M) expenses, alongside a $1.6 million non-cash loss tied to the amendment of its Senior Unsecured Convertible Promissory Note in connection with the March–April 2026 private placement. That financing generated $21.2 million in gross proceeds, triggering the automatic conversion of all Series A Preferred Stock into common shares and materially strengthening liquidity — cash and equivalents surged to $24.5 million as of March 31, 2026, with an additional $5.2 million received in April. Management explicitly links this capital infusion to advancing the Phase 1b registrational study of SER-252, its lead POZ-platform candidate for advanced Parkinson’s disease, which dosed its first patient in February 2026. The trial’s design — randomized, double-blind, placebo-controlled with single- and multiple-ascending-dose arms across U.S. and Australian sites — targets TFL data from the SAD component in H1 2027. With no forward guidance disclosed and no revenue generation, the company remains fully dependent on capital markets and partnership milestones; however, the successful PIPE close and initiation of a registrational study represent critical de-risking steps for both SER-252 and the broader POZ Platform™, particularly given its non-exclusive license agreement with Pfizer for LNP delivery applications. Investors should monitor upcoming clinical data timelines and cash runway sustainability beyond current balances.